PROGESTOGEN THERAPY FOR DES-INDUCED CV ABNORMALITIES

临床证据表明，黄体酮可能会降低 己烯雌酚生殖道腺病的存在 (DES)-暴露在人类身上的女性。药效的测试 孕酮治疗暴露于DES的女性 在这项研究中提出使用新生儿雌激素处理的小鼠 作为模型系统。新生的雌性BALB/c小鼠将收到 皮下注射雌二醇(E2)1或25微克，共5次 出生后24小时开始的天数。小鼠将断奶 在25天内，并随机分布在以下各项中 试验组：A)不接受进一步治疗的动物， B)接受大剂量普罗维拉(R，C)治疗的患者 大剂量普维拉(R)和乙基雌二醇-17，以及D)那些 仅接受乙炔雌二醇17B。所有团体都将收到 通过硅胶植入物进行常规治疗。治疗将在以下时间开始 两个月大，将持续一年。老鼠来自 每组每隔三个月挑选一次，并接受 连续10天阴道涂片后处死。 一半的宫颈阴道会被冷冻，然后 分析细胞质和核内P受体的存在 (PR)和E(ER)受体。简历的另一半也会 冰冻切片进行组织学检查。

Clinical evidence suggests that progesterone may reduce the presence of adenosis in the genital tracts of diethylstilbestrol (DES)-exposed human females. Testing of the efficacy of progesterone therapy for the DES exposed human female is proposed in this study using the neonatally estrogen treated mouse as the model system. Neonatal female BALB/c mice will receive subcutaneous injections of 1 or 25 ug of estradiol (E2) for five days beginning 24 hours following birth. The mice will be weaned at 25 days and randomly distributed among the following experimental groups: A) animals receiving no further treatment, B) those receiving a high dose of Provera (R, C) those receiving a high dose of Provera (R) and ethinyl-estradiol-17, and D) those receiving ethinyl-estradiol 17B only. All groups will receive normonal treatment via silastic implants. Treatment will begin at two months of age and will continue for one year. Mice from each group will be selected at three month intervals and subjected to vaginal smears for ten consecutive days followed by sacrifice. One half of the cervicovaginal (CV) tract will be frozen and then analyzed for the presence of cytoplasmic and nuclear P receptor (PR) and E (ER) receptor. The other half of the CV tract will also be frozen and sectioned for histologic examination.